The effects of coenzyme Q10 on women with breast cancer: a systematic review protocol

Megan Mathews

DOI: https://doi.org/10.11124/jbisrir-2014-1140

2014-08-01

JBI Database of Systematic Reviews and Implementation Reports

Abstract:Review objective The aim of this review is to identify the effects of coenzyme Q10 on women with breast cancer. More specifically, the objective is to identify the effects of coenzyme Q10 on:Death/survival rateStandard blood, immune and tumor parametersPrimary and secondary tumorsRecurrence of cancerAdverse eventsAdherence to conventional treatmentImpact on conventional treatmentMeasures of quality of life. Background Excluding basal and squamous cell skin cancers, breast cancer was the most common cancer amongst Australian women in 2009.1 Breast cancer comprised 27.4% of all new cancer cases in Australian women and it has been estimated that one in eight Australian women will be diagnosed with breast cancer before they reach 85 years of age. Breast cancer is the leading cause of disease burden amongst Australian women.2 At the end of 2008, there were 159,325 Australian women alive who had been diagnosed with breast cancer in the preceding 27 years.2 Over the last four decades, the incidence of breast cancer has increased globally3, with the highest incidence in developed countries such as Australia1,2, New Zealand4, North America5, England6 and Western Europe.7 Australian data show that between 1982 and 1995, the age‐standardized incidence rate rose from 81.1/100,000 to 115.9/100,000 and thereafter stabilized at 113.5/100,000.1 Global population growth will further increase the number of women diagnosed with breast cancer. In Australia: 13,668 women were newly diagnosed with breast cancer in 2009; it is estimated that 15,000 women will be diagnosed during 20131 and that this number will rise to around 17,210 women by 2020.2 In the USA, new breast cancer cases rose from 182,800 in 2000 to 226,870 in 2012.8 The number of women with breast cancer in the USA is expected to double by the year 2050.3 Survival rates for women with breast cancer In 2010, breast cancer was responsible for 6.7% of all Australian cancer‐related deaths and 15.3% of Australian cancer‐related deaths in women, equating in 2013 to approximately 3000 deaths.1,2 On the positive side, relative survival rates after diagnosis have significantly improved worldwide.1–3,5‐8 Australian data shows that between 1994 and 2010 the age‐standardized mortality rate for breast cancer decreased by 30%, from 30.8/100,000 to 21.6/100,000. During the period 1982‐1987, five‐year survival was 72%, while during 2006‐2010 it rose to 89.4%.1,2 Diagnosis and conventional treatment for breast cancer This significant improvement in five‐year survival rates is partly due to mass screening programs, early cancer detection and better conventional treatment regimens (surgery, radiotherapy and chemotherapy).9 For example, it is clear that size of a tumor at diagnosis strongly predicts prognosis. Australian data for 1997‐2006 show that five year relative survival for women with breast cancer was 98.2% for 0‐10mm tumors, compared to 73% for women with 30mm tumors.2 Breast cancer is classified according to its histo‐pathological type, the tumor grade and stage and the expression of tumor proteins and genes.10, 11 Classification indicates the presence, extent and aggressiveness of a cancer as well as the most appropriate treatment options. Prognosis, or the effectiveness of a cancer treatment regime, is reflected in the patient's history, physical examination, ongoing test results, and both positive and negative responses to treatment.11‐1 Tests commonly used to measure the presence of cancer and the effectiveness of treatment include biochemical markers, biopsies and imaging scans These tests assess the patient's general health, inflammation levels (erythrocyte sedimentation rate, c‐reactive proten)14, whether the cancer has spread to organs (liver, bone, bone marrow), as well as levels of predictive biomarkers (Ca15.3, CA125, CEA ) that are associated with tumor type and activity.15 Treatment depends on the type, grade and staging of the breast cancer, as well as the health of the patient.12,13,16 The three standard broad treatment options recommended by conventional medicine oncologists are surgery, radiotherapy and chemotherapy, including hormonal therapy. The appropriate treatment regime for a patient might be any combination of these options. Rise in the use of complementary and alternative medicine (CAM) by women with breast cancer The last four decades have witnessed a global increase in the use of complementary and alternative (CAM) therapies.17–24 This period has also seen an increase in women's use of CAM therapies for treating breast cancer.25‐29 For example, a Canadian study comparing survey data from 1998 and 2005 reported that CAM use amongst women with breast cancer rose from 66.7% in 1998 to 81.9% in 2005.25 In addition, a 2005 Australian survey found that women with breast cancer are more likely to use CAM therapies than other women with or without cancer.26 They used CAM therapies soon after diagnosis, during treatment, as well as years later. A 2004 USA study showed that 66% of women diagnosed with breast cancer were using CAM therapies on average 3.5 years after diagnosis.27 The main reasons reported by women with breast cancer for using CAM therapies included reducing side effects of conventional treatment, enhancing recovery and improving general health, boosting the immune system, taking control and curing the cancer.29 CAM consists of a group of diverse healthcare systems that share common beliefs.30‐32 The aim of treatment is to address the underlying cause(s) of a disease rather than its symptoms; the body, mind, spirit and ecology need to be treated as an integrated whole and health is a positive state of wellbeing, not the absence of measurable disease.30–32 The main tools used by CAM practitioners include mind‐body interventions, biologically‐based treatments, manipulative and body‐based methods and energy therapies.30–32 CAM practitioners believe their approach strengthens and utilizes the body's vital force and healing capacity.30‐32 Factors that have contributed to the rise in CAM usage included the introduction of traditional healthcare systems from indigenous and foreign cultures33, growth of the wholefood and health products movements33,34, global increase in rates of chronic illness35,36, extension of health insurance coverage to include CAM treatments37, inclusion of CAM modalities in physician university training and hospital treatments38 and the substantial rise in government funding for CAM research and treatment centers.30‐32 A 2012 systematic review of surveys of UK conventional medicine physicians revealed that around 20% of physicians were practicing CAM therapies with their patients and 39% were referring patients to CAM practitioners.39 While most patients always told their CAM practitioner about their conventional treatments, less than 50% always told their conventional medicine practitioner they used CAM.25‐27 The consequence can be that general practitioners and oncologists are unaware of the CAM therapies patients are using and therefore unable to assess their safety and effects on conventional treatment and prognosis. An additional consequence is that general practitioners and oncologists are unable to advise patients about the evidence‐based use of CAM therapies to improve patient tolerance of conventional treatment, as well as treatment outcomes. Coenzyme Q10 Coenzyme Q10 is a specific CAM treatment for breast cancer. A 2002 survey of licensed North American naturopathic physicians found that 77% had treated breast cancer and their most common specific treatments were coenzyme Q10, vitamin C and the Hoxsey herbal formula.40 Coenzyme Q10 was first isolated in 1957 and its chemical structure was ascertained in 1958.41 Coenzyme Q10 is a fat‐soluble, vitamin‐like, compound that is found in all mammalian cellular systems and almost every fluid, cell, tissue and organ.42,43 The body synthesizes coenzyme Q10 and also absorbs it from food and supplements.42,43 Highest natural levels are found around age 25 years and decline with ageing, stress, poor diet and illness.41,42 Coenzyme Q10 is found in two main redox states ‐ the fully reduced form, ubiquinol and the fully oxidized form, ubiquinone. Coenzyme Q10 moves between these two states by donating or accepting electrons and this allows it to play crucial roles in the electron transport chain of cellular energy production and as an antioxidant.42‐44 Coenzyme Q10 is involved in cell processes that characterize the differences between healthy and cancerous cells.43,45 The three most important areas of coenzyme Q10 function pertaining to cancer are as follows: Coenzyme Q10 it is an essential component of the electron transport chain in aerobic respiration (oxidative phosphorylation) that mostly occurs in mitochondria.42,43 This very efficient process converts fatty acids and carbohydrates into 30‐36 adenosine triphosphate molecules (ATPs)/molecule glucose and provides around 95% of the cell's energy requirements for growth, repair and reproduction. In contrast, cancer cells mostly use anaerobic respiration, a relatively inefficient process with much lower energy yields ‐ 1‐2 ATPs/molecule glucose. Energy production is one of the fundamental metabolic differences between healthy and cancer cells.45 Coenzyme Q10 is a ubiquitous and endogenous fat‐soluble antioxidant that protects fat‐rich molecules and structures from free radical attack. It also helps re‐activate spent antioxidants such as tocopherol and ascorbate.43,44 Breast cancer tissue has higher levels of oxidative stress and lipid peroxidation than non‐malignant breast tissue.46‐48 Coenzyme Q10 has been shown to reduce levels of tumor‐associated cytokines (TNF‐alpha, IL‐2), superoxide anions and DNA damage in peripheral lymphocytes.43,49 It also helps increase IgG levels, T4/T8 ratios and thymus function.50 Coenzyme Q10 plays roles in redox control of cell growth and signaling, membrane channel structure and fluidity, hydrogen peroxide production, apoptosis, gene expression and formation of thiol groups.51‐53 Coenzyme Q10 plays an important role in the adjuvant treatment of a wide range of diseases54–60, including cancer.61‐63 Some women with breast cancer have lower than normal range plasma and tissue levels of coenzyme Q10 and this is associated with a poorer prognosis.61‐66 Supplementation with coenzyme Q10 either in combination with other nutrients67–72, or oral hormonal therapy (Tamoxifen) plus nutrients73–76 is associated with tumor regression and increased years of survival. As these studies often utilize small sample sizes and/or observational study designs, a synthesis of studies in this area will better determine whether coenzyme Q10 is effective and safe for women with breast cancer. Coenzyme Q10 can be administered orally or intravenously. No serious adverse events have been reported for coenzyme Q10 taken alone, but it can augment warfarin treatment.77,78 The most common minor adverse events include dizziness, headache, reflux, nausea, insomnia, fatigue, irritability, light sensitivity, right upper abdominal pain and raised liver enzymes.77,78 In summary, due to their widespread use, CAM therapies are a significant practice issue for GPs and oncologists managing breast cancer patients. Very little is known about what specific CAM therapies are being used by women with breast cancer and whether they interfere, complement or augment conventional treatment. There is a pressing need to critically review the literature concerning coenzyme Q10 and determine its evidence‐based role in the treatment of breast cancer. A preliminary search of the JBI Database of Systematic Reviews, the Cochrane Library, PubMed and CINAHL has shown that to date, no systematic review has addressed this issue.